Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 233149

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Drug Discovery
  • Therapeutic
  • Assay
  • Disease
  • Cancer
  • Nerve
  • cardiac
  • Proteins
  • Data Management
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233149

License Grant
With this agreement, Licensee may secure back from Taiwan Licensor CART Identified Compounds.   If,  the Licensor has not licensed the CART Identified Compound to a Third Party and/or to Arena, and, has not filed an IND with a Regulatory Agency for a Drug Product, and, has not filed an IND with a Regulatory Agency for a Drug Product and the Drug Product has not been introduced into at least one(l) human volunteer, within the time period allotted, then, Licensee may secure back any CART Identified Compound and/or Drug Product from the China Licensor.

This is for a Licensor Selected Receptor and corresponding CART Identified Compound and/or Drug Product only if all three of the premises which give rise to Licensees unilateral right to request return occur with respect to such Licensors Selected Receptor and corresponding CART Identified Compound and/or Drug Product.

License Property
CART identified compounds means a compound, and/or a Derivative of a CART Identified Compound, that has been identified as a modulator of a Licensor Activated Receptor by Licensor during the term of this Agreement or by Licensee Screening.

Drug product means a therapeutic product comprising a CART Identified Compound.

Licensors Activated Receptor means a Licensor Selected GPCR to which the Licensee Activation Technology has been applied.

G Protein Coupled Receptor and GPCR means an Endogenous cell-surface receptor defined by having three (3) intracellular loops, three (3) extracellular loops, an amino terminus and a carboxy terminus.

Field of Use
Licensee is a biopharmaceutical organization focused on the discovery and development of innovative therapeutics.

CART Technology allows for ligand-independent, direct identification of small molecule compounds that regulate the activity of G protein-coupled receptors. CART is particularly useful with respect to orphan GPCRs that are estimated to comprise approximately 2% of the human genome. Such ligand independent screening is made possible by genetic alteration of these receptors, using widely applicable and proprietary genetic cassettes. Licensee has established CART collaborations with several pharmaceutical and biotechnology organizations. Licensee is also using the Melanophore Technology in combination with its CART Technology for internal drug discovery purposes.

IPSCIO Record ID: 203543

License Grant
Licensor grants to the Licensee of China and its Affiliate, with respect only to the Licensees Activated Receptor that is the subject of the Screening Assay Notice
(a) an exclusive right and license under the Technology, exclusive even as to Licensor,  to use, have used, sell, have sold, import, have imported, further develop, improve and otherwise exploit in any manner the Licensees Activated Receptor, for the purpose of identification of CART Identified Compound(s) in the Territory, and
(b) an exclusive right and license under the Technology, exclusive even as to Licensor, to develop, manufacture, have manufactured, promote, market, sell, distribute and, license CART Identified Compound(s) and/or Drug Product(s) in the Territory.
License Property
CART identified compounds means a compound, and/or a Derivative of a CART Identified Compound, that has been identified as a modulator of a Licensee Activated Receptor by Licensee during the term of this Agreement or by Licensor Screening.

Drug product means a therapeutic product comprising a CART Identified Compound.

Licensees Activated Receptor means a Licensee Selected GPCR to which the Licensor Activation Technology has been applied.

G Protein Coupled Receptor and GPCR means an Endogenous cell-surface receptor defined by having three (3) intracellular loops, three (3) extracellular loops, an amino terminus and a carboxy terminus.

Licensor is an emerging biopharmaceutical company focused principally on discovering drugs that act on an important class of drug targets called G protein-coupled receptors, or GPCRs. Licensor has developed a technology called Constitutively Activated Receptor Technology, or CART, that can be applied to GPCRs and other classes of receptors to identify drug leads. Licensor believesthat CART is a more efficient drug discovery technique than traditional drug discovery techniques.

Field of Use
Licensee is a biopharmaceutical organization focused on the discovery and development of innovative therapeutics.

IPSCIO Record ID: 203440

License Grant
Licensor grants to the Japanese Licensee the following with respect only to each Licensee Activated Receptor that is the subject of the Screening Assay Notice
(a) an exclusive right and license under the Technology, exclusive even as to Licensor, to use, have used, sell, have sold, import, have imported, further develop, improve and otherwise exploit in any manner the Licensee Activated Receptor, for the purpose of identification of CART Identified Compound(s) in the Territory, including the right to sublicense the rights granted to Licensee by Licensor, and
(b) an exclusive right and license under the Technology, exclusive even as to Licensor, to develop, manufacture, have manufactured, promote, market, sell and distribute CART Identified Compound(s) and/or Drug Product(s) comprising a CART Identified Compound in the Territory ,including the right to sublicense the rights granted to Licensee by Licensor.
License Property
Licensor Activation Technology means a Licensor proprietary approach, referred to by Licensor as CART Technology, to identifying, selecting and altering a region(s) within a G Protein Coupled Receptor that, when altered, leads to or enhances ligand-independent constitutive activation of the altered receptor.

Licensor Patent Rights means all present and/or future patents to the extent they are directed to
(1) Licensor activation technology applied to CA receptors and/or  (2) Licensor Cloning applied to CA Receptors and/or  (3) CA Receptors and/or  (4) Licensee Activated Receptor(s) and/or  (5) CART Identified Compound (s) and/or  (6) Drug Product(s) and/or  (7) Screening Assay(s).

CART Identified Compound(s) means a compound, and/or a Derivative of a CART Identified Compound, that has been identified as a modulator of a Licensee Activated Receptor by Licensee or Licensees Licensee(s) during the term of this Agreement or by Licensor Screening.

CA Receptors are endogenoues receptors relating to Cocaine and Amphetamine regulated receptor.

CART Technology allows for the direct identification of modulators of G protein-coupled receptors in a ligand-independent manner, making the technology particularly useful with respect to orphan GPCRs which are estimated to comprise approximately 2% of the human genome. Such ligand independent screening is made possible by genetic alteration of these receptors, using routinely applicable and proprietary genetic cassettes.

Field of Use
Licensee is a pharmaceutical company focused on contributing to the maintenance and improvement of consumers health by creating and providing quality drugs, related healthcare products and information services that satisfy consumers with various lifestyles.

IPSCIO Record ID: 209557

License Grant
Licensor grants a non-exclusive right and license to make, use, have used, further develop, improve and otherwise exploit Licensor Technology and Improvements within the Field in the territory to
(a) make and use CART Activated Receptor(s) to screen the Licensees Chemical Library or Compounds(s) or other compounds in an Enabled Screening Assay or Licensees Screen for the identification of CART Identified Compounds(s), and to use such CART Identified Compound(s) for the use, development, manufacture, promotion, marketing, sale, importation, and distribution of CART Identified Compound(s) and/or Drug Product(s), including the right to sublicense the rights granted to Licensee by Licensor hereunder; and
(b) use Licensor Technology on GPCRs contained in the Receptor Pool, including use to create CART Activated Receptors and to use such CART Activated Receptors in a Licensees Screen to identify CART Identified Compounds. No other right, title, interest or license is granted, implicitly or explicitly, by Licensor to Licensee under this Agreement.
License Property
Licensor is a biopharmaceutical organization focused on the discovery and development of innovative therapeutics.

CART Technology means Licensor Technology for enhancing the signal of a GPCR with or without the binding to the GPCR of the Endogenous ligand corresponding to such GPCR.  GPCRs relate to expression within the central nervous system, cardio-vascular system, the pituitary gland, the pancreas or the thyroid gland, amino acid or nucleic acid sequence, and cancerous condition.

Drug Product means a composition which has been packaged and labeled and is ready for administration for human or animal therapy comprising at least one (1) CART Identified Compound.

Field of Use
Licensee is in the business of discovering, developing, manufacturing, and marketing pharmaceutical products and animal health care products.

The Field means all human and animal pharmaceutical applications of a CART Identified Compound and/or Drug Product.

IPSCIO Record ID: 203433

License Grant
Licensor grants to the United Kingdom Licensee with respect only to the CART Identified Ingredients, an exclusive right and license, exclusive even as to Licensor, to make, have made, use, have used, further develop, improve and otherwise exploit in any manner, including the right to sub-license, the CART Identified Ingredients within the Field.
License Property
CART Identified Ingredient. For each CART Activated Receptor subject to screening, Arena shall use Best Reasonable Commercial Efforts to identify at least one (1) CART Identified Ingredient and to determine the ICso Value and/or EC5o Value, whichever is applicable, with respect to such CART Identified Ingredient. Upon identification of each such CART Identified Ingredient, Licensor shall provide Identified Ingredient Notice to Licensee.
Field of Use
The parties desire to collaborate to identify broad-spectrum modulators of specific G protein-coupled receptors to enhance the discovery processes in the fragrances, flavors and food industry.

The Field means the non-therapeutic, non-insecticidal, non-herbicidal, non-medicinal uses of CART Identified Ingredients for modulation of Sensory GPCRs; for purposes of clarity, the definition of Field includes, but is not limited to, aroma-based therapeutics.

Licensor primarily focuses the application of CART to GPCRs that are believed to be therapeutically relevant, i.e. targets for use in the discovery of potential human therapeutics. However, because all GPCRs have the same structural shape, CART can be applied to non-therapeutic GPCRs as well as non- human GPCRs such as plant and insect GPCRs. 'Olfactory' and 'gustatory' GPCRs, those that are the subject of the agreement with Licensee, are involved with the processing of both odor and taste sensations, respectively. An objective for applying CART to these types of receptors is to identify chemical compounds that may affect odor and flavor.

Olfaction is a chemoreception that forms the sense of smell. And gustatory is concerned with tasting or the sense of taste.

IPSCIO Record ID: 329676

License Grant
For the license grant for Exclusive Screens Licensor grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice the Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee.

For the license grant for Non-Exclusive Screens, License grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice Non-Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee, during the term of the Research Programs, but in no event for less than nine months after Licensee receives Materials and other information from Licensor identifying and enabling Licensee to use such Non-Exclusive Screen.

License Property
Licensor has the exclusive rights to certain technology involving the transfection and expression of G-protein- coupled receptors into yeast.  Licensor exploits similarities between the yeast and human genome to identify new drug discovery targets.

The Autocrine System shall mean that part of Licensors Technology whereby any yeast cells into which human Receptors have been inserted and grow in response to compounds produced and secreted by the same yeast cells.

Compound shall mean any Lead Compound or any Analog of any Lead Compound.

Receptor shall mean any human, G-protein-coupled, seven transmembrane receptor (including, without limitation, genes, vectors and cDNAs), and shall include any Licensee Receptor or Other Receptor.

Licensee Receptor shall mean a Receptor which is proprietary to Licensee and is provided by Licensee to Licensor for use in the Research Programs, or a Receptor which is proprietary to Licensee and is cloned or obtained by Licensor pursuant to research performed under the Research Programs, or a Receptor provided by Licensee to Licensor for use in the Research Programs which is deemed to be a Licensee Receptor.

Technology shall mean all inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, Patents and Know-How owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses, and relating to or derived from Licensors yeast-based, human G-protein-coupled receptor technology, or the Research Programs.

The Patents are titled
Expression of G Protein Coupled Receptors in Yeast, Yeast-Based Peptide Libraries for identification of G Protein-Coupled Receptor Agonists and Antagonists, and, Functional Expression of Mammalian Adenylyl cyclase in Yeast.

Field of Use
The field of use is screening assays.

Licensee recognizes that the technology represents a valuable source of development of screening assays for the discovery of potential products for manufacture, use and sale in the Territory.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 203296

License Grant
For the Non-Exclusive Research License to Licensors Base Technology,  Licensor grants a non-exclusive, world-wide license under the Base Technology and Collaboration Technology to conduct research and Development activities with respect to Targets, Hits, Research Compounds, Lead Compounds and IND Candidates pursuant to the Research Plan.   Licensor also grants the right to sublicense or transfer the rights granted to Licensee under the Collaboration Technology to  Affiliates; and to Third Parties.
License Property
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

Gene Expression Modulation by Small-molecules (GEMS) is PTC’s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.

Field of Use
The Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.

IPSCIO Record ID: 283198

License Grant
The Licensee and Swiss Licensor are establishing a research program to identify and validate a limited number of antibacterial targets and to develop a select number of validated assays for high-throughput screening to identify new lead compounds active against such validated targets for the development of drugs.

For Discontinued Licensor Compounds
—  Globally Discontinued Licensor Compounds, in the event that the Swiss Licensor determines, or is forced, to discontinue the development or the global commercialization of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, such Licensor Compound or Active Licensee Compound Derivative being referred to herein as a Globally Discontinued Novartis Compound, and if Licensor, at its sole discretion, decides to license to a Third Party such Globally Discontinued Licensor Compound, then Licensor shall notify Licensee in writing of the occurrence of the above. Licensee shall then have the right of first refusal.

—  Locally Discontinued Licensor Compounds, in the event that in any country, following the First Commercial Sale of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, there is a continuous one (1) year period in which no such Licensor Product is sold in such country, and if Licensor, at its sole discretion, decides to license to a Third Party such Locally Discontinued Licensor Compound, Licensor shall notify Licensee in writing of the occurrence of the above. Licensee then
shall have the right of first refusal.

This agreement also includes exclusive, non-exclusive and co-exclusive grants from Licensee to Licensor.

License Property
The know-how, expertise and intellectual property rights pertain to anti-infective drug discovery and to a proprietary drug discovery technology known as VITA TM which couples the validation of the inhibition of a target in an animal model during an established infection with assay development and screening for the discovery of novel drug leads.

VITA TM or Validation In Vivo of Targets for Anti-infectives shall mean Licensors proprietary technology for the validation of anti-infective targets during an established infection in a mouse model system and the development of assays.

The technology couples the validation of target proteins in a pathogen during an established infection in an animal with assay development. The assay is used in high throughput screening to discover novel drug leads that act on therapeutically relevant targets. It is broadly applicable to a number of different targets, including proteins encoded by open reading frames (ORFs), which have previously been intractable to traditional screening paradigms.

Field of Use
Licensee possesses know-how, expertise and intellectual property rights pertaining to antiinfective drug discovery and to a proprietary drug discovery technology known as VITA(TM) which couples the validation of the inhibition of a target in an animal model during an established infection with assay development and screening for the discovery of novel drug leads.

IPSCIO Record ID: 222557

License Grant
Licensor agrees to grant, and hereby grants to Licensee an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology (exclusive even as to Licensor and its Affiliates), to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory.  It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

Licensor agrees to grant, and hereby grants, to Licensee an exclusive license (exclusive even as to Licensor and its Affiliates), under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

License Property
The proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.

Combination Product shall mean a Product which comprises two (2) or more active therapeutic ingredients at least one (1) of which is an Agreement Compound or a Licensee Compound.

Library Compound shall mean any compound which is contained in a Discovery Library or Optimization Library hereunder.

Target shall mean a biomolecular entity (including, without limitation, receptors, enzymes, nucleic acids and proteins, and/or fragments thereof) that a small molecule is screened against in order to determine whether the small molecule demonstrates a specific biochemical or pharmaceutical effect.

Library shall mean any chemical compound library prepared by Licensor employees working on the Collaboration, and/or Licensee employees working at Licensors facilities on the Collaboration,  under the terms of this Agreement using (i) combinatorial chemistry techniques or (ii) such other techniques as may, from time to time, be agreed by the Parties.

Field of Use
This agreement pertains to the drug industry relating to therapeutic, treatment or prevention of diseases and conditions in human beings.

Licensor's combinatorial chemistry technology will accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.

IPSCIO Record ID: 227245

License Grant
Licensor and Licensee are entering into this Agreement to provide for Licensor to conduct further research and development involving Licensor Technology in exchange for certain funding by Licensee and for Licensor to license, and Licensee and its Affiliates to obtain a license for, the use and practice of Screens in Licensees research and development.
License Property
Product shall mean any product which uses as one of its active ingredients a Compound which is developed by or on behalf of Licensee, each developed for a therapeutic indication based on the biological activity demonstrated by the relevant Lead Compound or the Natural Ligand in the relevant Screen.

Licensor Technology shall mean (a) prior to the Effective Date, all proprietary inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses (including any academic collaborations), and relating to technology involving the transfection and expression of Targets into yeast cells and the development of such yeast cells as Screens for the discovery of potential products; and (b) after the Effective Date, all proprietary inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, owned by Licesor or to which Licensor has the rights to grant licenses or sublicenses, and utilized or arising under the Research Program, provided Licensor Technology shall not include any Licensee Technology as defined of the definition of Licensee Technology. For the purposes of clarity, the identity, sequence information, and structure of the Natural Ligand for any Third Party Target, or other information on the biological function of such Third Party Target are not Licensor Technology and may be provided by Licensee to Third Parties.

Surrogate Ligand shall mean any agonist molecule whose biological activity is identified or confirmed by Licensor through the use of Licensor Technology or Licensee Technology licensed to Licensor and which is biologically active against a Target thereby causing a cellular response and which is not a Natural Ligand or Analog of such Natural Ligand for such Target.

Natural Ligand shall mean a ligand produced by a human cell or a human pathogen whose biological activity is identified or confirmed through the use by Licensee (or on behalf of Licensee) or Licensor of Licensor Technology, which ligand is biologically active against a Target thereby causing a cellular response and which is reasonably confirmed to be a ligand for the Target, provided any of such Licensor Technology is proprietary to Licensor at the time of such use by Licensee or Licensor as the case may be.

Field of Use
This agreement pertains to the drug industry relating to certain technology involving the transfection and expression of certain Targets into yeast, the identification of Surrogate Ligands and Natural Ligands for certain Targets, and the development of yeast strains suitable for drug discovery research.

The research collaboration and license agreement seeks to elucidate the function of orphan G protein-coupled receptors included within the collaboration and to create high-throughput screens to discover chemical compounds (i.e., potential drugs) that interact with these receptors.

IPSCIO Record ID: 249765

License Grant
For the License to Licensed Products,  Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.

This agreement also includes non-exclusive grants for research.

License Property
Licensor has certain technology and knowhow, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.

ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.

Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.

Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.

Field of Use
The Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 215175

License Grant
The parties wish to collaborate in a chemical lead and drug discovery program.  This agreement has an exclusive period.

Subject to and following the decision of Licensor or its licensee to not develop and commercialize with Due Diligence an Active Compound, a Development Compound or Product, as the case may be, Licensor shall grant to Licensee a license, with the right to sublicense, under those Collaboration Patents and know-how which are resulting from the Research Program and related exclusively to the Returned Compound, to make, have made, use, have used, sell, have sold, import and export such Returned Compound in the Territory.

License Property
The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.
Field of Use
The Field means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed.

IPSCIO Record ID: 249718

License Grant
Licensor grants an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and undivided interest in any Program Intellectual Property and Program Patent Rights that are jointly owned by Licensor and Licensee, as embodied in or related to Designated Compounds, to identify, research, develop, make, have made and use such Designated Compound to develop Licensed Products and to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products; provided, that the exclusivity of such license shall be subject in the case of Generic Patent Rights to the retained rights.
License Property
The licensed property is
(a) the NeoMorph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Preliminary Compounds,
(e) the Primary Active Compounds,
(f) the Selected Compounds, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof made by Licensor, and
(g) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Programs.

The NeoMorph Screening Library consists of approximately 10,000,000 diverse small organic compounds.

Field of Use
Field means the diagnosis, prevention and/or treatment of any and all diseases in humans.

Licensor synthesize small molecule compounds as mixtures in a format that enables ALIS to efficiently screen proteins. Our proprietary NeoMorph library, consisting of over 10 million diverse small molecules, is stored as approximately 5,000 mixtures, each containing approximately 2,000 mass-encoded compounds. We use proprietary software to ensure that each small molecule compound within a mixture can be uniquely identified by its mass. This obviates the need for artificial tagging methods, which adds preparation time and cost, and may interfere with the screening process.

Under this drug discovery collaboration, Licensor agreed to screen a number of proteins supplied to us by Licensee. Licensor maintains the option to develop some or all of the small molecule compounds Licensor identify.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.